Dynamic Technology Lab Private Ltd bought a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,537 shares of the biopharmaceutical company’s stock, valued at approximately $357,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALXN. Fiduciary Trust Co. acquired a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $111,000. Dupont Capital Management Corp bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $156,000. BT Investment Management Ltd bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $165,000. Penserra Capital Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $160,000. Institutional investors own 94.15% of the company’s stock.

Several equities research analysts recently weighed in on ALXN shares. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. TheStreet cut shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Royal Bank Of Canada increased their target price on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Finally, Stifel Nicolaus cut their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $155.06.

In other news, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the transaction, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.44, for a total transaction of $636,300.00. Following the transaction, the executive vice president now directly owns 26,092 shares in the company, valued at $3,794,820.48. The disclosure for this sale can be found here. Insiders have sold a total of 5,330 shares of company stock valued at $774,851 in the last ninety days. Company insiders own 4.35% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $108.96 on Friday. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market cap of $24,532.61, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 1.19 and a beta of 1.19.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the previous year, the business earned $1.23 EPS. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Dynamic Technology Lab Private Ltd Invests $357,000 in Alexion Pharmaceuticals, Inc. (ALXN)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/02/dynamic-technology-lab-private-ltd-invests-357000-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.